# A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs

> **NCT00828971** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 16 (actual)

## Conditions studied

- Infectious Diseases

## Interventions

- **DRUG:** Avelox (Moxifloxacin, BAY12-8039)
- **DRUG:** Amoxicilline/clavulanic

## Key facts

- **NCT ID:** NCT00828971
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-09
- **Final completion:** 2009-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00828971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00828971, "A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00828971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*